Health Innovation Next Generation Payment & Pricing Models

HealthHORIZON-RIAID: 101095593
EC Contribution
€39,625
Consortium Size
18 orgs
Start Year
2023
Summary

The variety of innovative technologies with the potential to revolutionize the delivery of health care means that the policy toolbox will need several pricing and payment models, adapted in their design and implementation according to the specific situation. Although there are examples of novel pricing and payment models, the lack of appropriate data infrastructure, legal barriers and unwillingness to adapt current systems often prevent their use. Therefore, the overall objectives of the Health Innovation Next Generation Pricing Models (HI – PRIX) project are: i) to map and formulate new pricing and payment schemes that can be used across technology classes, therapeutic areas, setting and healthcare systems/geographies together with a related set of principles that may guide successful adjustment and flexible implementation to the context of use; ii) to investigate the impact on competitiveness, innovation, equity and affordability of a pipeline of contracting modalities for health innovations; iii) to address the challenges and concerns of payers, manufacturers, healthcare professionals, and patients about different models of pricing by sustaining an effective dialogue across stakeholders’ groups about the trade-offs between affordability, innovation and patient access. Coordinated by Bocconi University, the HI-PRIX Consortium involves 18 partners from 10 European countries, including academic institutions, public authorities, healthcare providers, and independent research organizations. Through theoretical models, quantitative simulation, qualitative research work and case-studies, this three-year project structured around 10 WPs, will generate new evidence on the role of public sector in R&D and indirect medical and environmental costs in pricing and reimbursement determinations, on the pricing dynamics over pharmaceutical products’ lifecycle, on the impact of policies and incentives on the competitiveness, innovativeness and equity in the healthcare system.

Consortium (18)

Project Results (21)

Source: CORDIS, the EU research results database.

Publications (18)
Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes
Frontiers in Medical Technology· 2026DOI
Baptiste Haon, Mira Hartmann, Sanae Akodad, Hilde Stevens, Lise Rochaix
Orphan medical devices: addressing the regulatory and access gaps in the EU and US
Frontiers in Public Health· 2026DOI
Sanae Akodad; Baptiste Haon; Lise Rochaix; Hilde Stevens
Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-Offs
PharmacoEconomics - Open· 2026DOI
Mario García-Díaz; Jorge Mestre-Ferrándiz; Jaime Espín
A Framework for Considering the Role of the Public Sector in R&D of Health Technology
Pharmaceutical Medicine· 2025DOI
Juan Carlos Rejon-Parrilla; David Epstein; Jorge Mestre-Ferrandiz; Jaime Espin
Applied Health Economics and Health Policy
Applied Health Economics and Health Policy· 2025DOI
Ardito, Vittoria; Banks, Helen; Tarricone, Rosanna
Applied Health Economics and Health Policy
Applied Health Economics and Health Policy· 2025DOI
Ludovico Cavallaro; Vittoria Ardito; Michael Drummond; Oriana Ciani
Frontiers in Pharmacology
Frontiers in Pharmacology· 2025DOI
García Díaz, Mario; Epstein, David Mark; Espín, Jaime
Frontiers in Psychiatry
Frontiers in Medicine· 2025DOI
Sanae Akodad, Michel Goldman, Hilde Stevens
Health Policy
Health Policy· 2025DOI
Claudia Wild; Ozren Sehic; Louise Schmidt; Daniel Fabian
Journal of Pharmaceutical Policy and Practice
Journal of Pharmaceutical Policy and Practice· 2025DOI
Louise Schmidt; Ozren Sehic; Ursula Theuretzbacher; Daniel Fabian; Claudia Wild
Journal of Pharmaceutical Policy and Practice
The origins of Novo Nordisk and Novartis products: piloting a framework to identify the public contributions· 2025DOI
Daniel Fabian; Ozren Sehic; Claudia Wild
Mechanisms Considering Public Investment in Pricing and Reimbursement Decisions of Medicines and Other Health Technologies: A Scoping Review
Applied Health Economics and Health Policy· 2025DOI
Mario García-Díaz; Zuzana Špacírová; Leticia García-Mochón; Jaime Espín
Medicare Negotiations Could Fuel, Not Stifle, Innovation.
Health Affairs Forefront· 2025DOI
Chuanzi Yue, Marisa Miraldo
AIHTA-Framework erleichtert Identifikation öffentlicher Beiträge zur Entwicklung von Innovationen im Gesundheitswesen
QUALITAS· 2024DOI
Ozren Sehic
Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review
PharmacoEconomics - Open· 2024DOI
ARDITO, VITTORIA; CAVALLARO, LUDOVICO; DRUMMOND, MICHAEL; CIANI, ORIANA
PharmacoEconomics
PharmacoEconomics· 2024DOI
Vittoria Ardito; Oriana Ciani; Michael Drummond
Social Science and Medicine
Social Science & Medicine· 2023DOI
Arianna Gentilini; Marisa Miraldo
ESG Performance, Debt Financing, and R&D Output: Evidence From the Healthcare Sector
Business Strategy and the EnvironmentDOI
Sarmad Ali; Oriana Ciani; Simone Ghislandi
Deliverables (2)
Other Results (1)
Periodic Reporting for period 1 - HI-PRIX (Health Innovation Next Generation Payment & Pricing Models)